Cytokinetics CYTK Liabilities Fair Value Adjustment
Liabilities Fair Value Adjustment at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesFairValueAdjustment.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's liabilities fair value adjustment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's liabilities fair value adjustment?
- Cytokinetics (CYTK) reported liabilities fair value adjustment of -$1.6M in Q1 2026.
- How has Cytokinetics's liabilities fair value adjustment changed year-over-year?
- Cytokinetics's liabilities fair value adjustment decreased by 141.0% year-over-year, from $3.9M to -$1.6M.
- What does liabilities fair value adjustment mean?
- Non-cash adjustments to the value of liabilities based on market conditions.
- How do you interpret liabilities fair value adjustment?
- Changes reflect market-driven revaluations of debt or contingent obligations.
- How does liabilities fair value adjustment compare across companies?
- Depends on the specific debt structure and accounting policies of the firm.